Hamilton Lane
HLNE
$87.71
+5.47%
Hamilton Lane is a private markets investment firm providing solutions to institutional and private wealth investors globally, specializing in private equity, real assets, and other alternative investments. As a dedicated private markets specialist with over 30 years of experience and approximately $986 billion in assets under management and supervision, the firm distinguishes itself through its extensive global platform and discretionary and non-discretionary advisory services. The current investor narrative centers on the stock's significant decline amid broader market volatility and concerns about private market valuations, though the firm's long-term track record and growing wealth channel are seen as potential catalysts for recovery.…
HLNE
Hamilton Lane
$87.71
Investment Opinion: Should I buy HLNE Today?
Rating: Hold. HLNE is a high-quality asset manager with strong margins and a healthy balance sheet, but the stock is in a deep downtrend and faces macro headwinds. The single analyst coverage provides limited guidance, but the forward PE of 11.0x is attractive relative to the industry average of 13x. Supporting evidence includes a net margin of 32.8% (vs. industry ~20%), ROE of 27.2%, low debt-to-equity of 0.39, and a dividend yield of 3.85%. However, the 47.1% annual price decline and high beta of 1.17 suggest continued volatility. Risks include further private market valuation declines, earnings disappointment, and lack of analyst support. This Hold would upgrade to Buy if the stock breaks above $90 (recent resistance) or if forward PE compresses below 9x, and downgrade to Sell if revenue growth turns negative or the dividend is cut. Overall, HLNE appears undervalued on a forward PE basis but overvalued relative to its recent price momentum.
Sign up to view all
HLNE 12-Month Price Forecast
HLNE's fundamentals are strong, but the stock is in a severe downtrend and faces macro headwinds. The forward PE suggests value, but the lack of analyst coverage and high beta add uncertainty. The base case of range-bound trading is most likely, with a 50% probability. A bullish stance would require a catalyst like earnings beat or market recovery, while a bearish stance would be triggered by further private market deterioration. The neutral stance reflects balanced risks and rewards.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Hamilton Lane's 12-month outlook, with a consensus price target around $126.86 and implied upside of +44.6% versus the current price.
Average Target
$126.86
0 analysts
Implied Upside
+44.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$94 - $174
Analyst target range
Only one analyst covers Hamilton Lane, which is insufficient for a robust consensus. The estimated EPS for the current fiscal year averages $7.26, with a range of $6.93 to $7.64, and estimated revenue averages $989 million. The lack of a price target and buy/sell ratings limits the ability to gauge sentiment. The limited coverage implies that HLNE is a small-cap or mid-cap stock with lower institutional interest, which can lead to higher volatility and less efficient price discovery. Investors should rely on fundamental analysis and monitor for additional coverage initiation or changes in existing estimates.
Drowning in data?
Find the real signal!
Bulls vs Bears: HLNE Investment Factors
HLNE presents a mixed picture: strong profitability, healthy balance sheet, and attractive forward valuation contrast with severe price decline, limited analyst coverage, and high beta. The bull case rests on the company's fundamental strength and potential for mean reversion, while the bear case highlights persistent selling pressure and macro sensitivity. The single most important tension is whether the market's pessimism is overdone or justified by deteriorating private market conditions. Currently, the bearish momentum is strong, but the fundamentals provide a compelling value argument for patient investors.
Bullish
- Strong Profitability and Margins: HLNE boasts a net margin of 32.8% and operating margin of 42.8%, significantly above the asset management industry average of ~20%, indicating efficient cost management and high profitability.
- Attractive Forward Valuation: With a forward PE of 11.0x, HLNE trades at a discount to the industry average forward PE of 13x, suggesting the market is pricing in a recovery and potential upside.
- Healthy Balance Sheet: The debt-to-equity ratio is low at 0.39 and the current ratio is 1.62, indicating moderate leverage and ample liquidity to weather market downturns.
- High Return on Equity: ROE of 27.2% demonstrates strong capital efficiency, well above the industry average, reflecting the firm's ability to generate profits from shareholder equity.
Bearish
- Severe Price Decline and Underperformance: HLNE has fallen 47.1% over the past year versus a 20.6% gain for the S&P 500, with a 1-year relative strength of -67.7%, indicating persistent selling pressure and market disfavor.
- Limited Analyst Coverage: Only one analyst covers HLNE, leading to less efficient price discovery and higher volatility; the lack of a consensus price target makes valuation assessment uncertain.
- High Beta and Macro Sensitivity: With a beta of 1.17, HLNE is 17% more volatile than the market, amplifying downside moves in risk-off environments, which is a concern given current macro uncertainty.
- Earnings Growth Expectations May Be Overly Optimistic: The forward PE of 11.0x implies expected earnings growth of ~50% over the next year, which is aggressive and may be at risk if private market valuations decline.
HLNE Technical Analysis
Hamilton Lane is in a pronounced downtrend, with the stock price falling 47.1% over the past year compared to a 20.6% gain for the S&P 500. The current price of $81.09 sits at 50.3% of its 52-week range (low $71.88, high $161.13), indicating it is closer to the low end, which could suggest a value opportunity but also reflects persistent selling pressure. The 1-year price change of -47.1% underscores a sustained bearish trend, with the stock trading well below its 52-week high of $161.13. Short-term momentum shows a mixed picture: the 1-month price change is +3.8%, while the 3-month change is -12.1%, indicating a recent bounce but still negative over the quarter. This divergence from the longer-term downtrend could signal a potential short-term reversal or a temporary pullback within a larger bearish structure. The relative strength versus the S&P 500 is deeply negative over all time frames, with a 1-month relative strength of -0.23 and a 1-year relative strength of -67.7, confirming persistent underperformance. Key support is at the 52-week low of $71.88, a break below which could signal further downside toward $65. Resistance is at the 52-week high of $161.13, and a breakout above that level would indicate a major trend reversal. The stock's beta of 1.17 suggests it is 17% more volatile than the market, meaning it tends to amplify market moves, which is consistent with its sharp decline. The current price is near the lower end of the range, and a break below $71.88 could accelerate selling, while a move above $90 (recent resistance) would be a positive sign.
Beta
1.17
1.17x market volatility
Max Drawdown
-54.1%
Largest decline past year
52-Week Range
$72-$161
Price range past year
Annual Return
-44.1%
Cumulative gain past year
| Period | HLNE Return | S&P 500 |
|---|---|---|
| 1m | +12.8% | +1.4% |
| 3m | -3.3% | +3.9% |
| 6m | -41.0% | +6.3% |
| 1y | -44.1% | +16.0% |
| ytd | -35.8% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HLNE Fundamental Analysis
Hamilton Lane's revenue trajectory appears stable, with estimated annual revenue of approximately $989 million for the current fiscal year, though specific quarterly figures are not provided. The firm's business model generates recurring fee income from assets under management, which provides a steady revenue stream. However, the lack of detailed quarterly data limits visibility into growth trends. Profitability is strong, with a net margin of 32.8% and an operating margin of 42.8%, indicating efficient cost management and high profitability typical of asset managers. Gross margin is 69.9%, reflecting the high-margin nature of advisory and management fees. Net income is positive, with EPS of $0.07 (likely quarterly) and a trailing PE of 16.6x, confirming profitability. The balance sheet is healthy, with a debt-to-equity ratio of 0.39, indicating moderate leverage, and a current ratio of 1.62, suggesting ample liquidity. Return on equity (ROE) is 27.2%, demonstrating strong capital efficiency. Free cash flow data is not provided, but the payout ratio of 56.9% and dividend yield of 3.85% indicate a commitment to returning capital to shareholders, supported by cash generation.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HLNE Overvalued?
Since net income is positive, the primary valuation metric is the PE ratio. The trailing PE is 16.6x, while the forward PE is 11.0x, implying that the market expects earnings growth to drive a lower multiple, which is a positive signal. The gap between trailing and forward PE suggests expected earnings growth of approximately 50% over the next year, which is aggressive but possible given the firm's earnings estimates. Compared to the asset management industry average PE of around 15x, Hamilton Lane's trailing PE of 16.6x is at a slight premium of 11%, which may be justified by its higher net margin (32.8% vs. industry average of ~20%) and strong ROE. The forward PE of 11.0x, however, is at a discount to the industry average forward PE of 13x, suggesting that the market is pricing in a recovery. Historical PE data is not available, but the current trailing PE of 16.6x is likely near the lower end of its historical range given the stock's 47% decline from its 52-week high, indicating that the market has de-rated the stock significantly. This could represent a value opportunity if earnings hold up, but also reflects pessimism about future growth.
PE
16.6x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: HLNE's revenue is tied to private markets, which are illiquid and subject to valuation uncertainty. The firm's net margin of 32.8% is high but could compress if fee income declines due to lower asset values. The debt-to-equity ratio of 0.39 is manageable, but any increase in leverage could strain the balance sheet. The payout ratio of 56.9% indicates a commitment to dividends, but if earnings fall, the dividend could be at risk. Market & Competitive Risks: HLNE's beta of 1.17 makes it sensitive to market downturns, and its 47.1% annual decline shows it has already been punished. The asset management industry is competitive, with players like Blackstone and KKR. Regulatory changes affecting private markets could also pose risks. The limited analyst coverage (only one) means less visibility and potentially higher volatility. Worst-Case Scenario: A prolonged bear market in private assets could lead to further declines in AUM and fee income, causing earnings to miss estimates. The stock could fall to its 52-week low of $71.88, representing a potential loss of 11.4% from the current price of $81.09. In a severe downturn, the stock could drop to $65, a 20% decline from current levels, based on historical max drawdown of 54.13% from the 52-week high.
FAQ
The key risks are: 1) Financial risk: earnings could decline if private market valuations fall, impacting fee income. The payout ratio of 56.9% could pressure the dividend if earnings drop. 2) Market risk: with a beta of 1.17, HLNE is highly sensitive to market downturns, as evidenced by its 47.1% annual decline. 3) Competitive risk: larger asset managers like Blackstone and KKR could gain market share. 4) Company-specific risk: limited analyst coverage (only one) leads to less efficient price discovery and higher volatility. The most severe risk is a further decline to the 52-week low of $71.88, a potential 11.4% loss from the current price.
The 12-month forecast is uncertain due to limited analyst coverage. In the bull case (25% probability), the stock could reach $100-$120 if private markets recover and earnings beat estimates. The base case (50% probability) sees the stock trading in a range of $80-$100 as conditions remain stable. The bear case (25% probability) could see the stock fall to $65-$80 if private market valuations decline further. The most likely scenario is the base case, with the stock remaining range-bound near current levels.
HLNE appears undervalued on a forward PE basis. The forward PE of 11.0x is below the asset management industry average of 13x, suggesting the market is pricing in pessimism. The trailing PE of 16.6x is at a slight premium to the industry average of 15x, but this is justified by higher margins (net margin 32.8% vs. industry ~20%). The PEG ratio of 1.67 implies the stock is fairly valued relative to expected growth. Overall, the valuation is attractive for value investors, but the stock's momentum is negative.
HLNE is a good buy for long-term, value-oriented investors who can tolerate high volatility. The stock offers a forward PE of 11.0x, a dividend yield of 3.85%, and strong profitability with a net margin of 32.8%. However, the stock has declined 47.1% over the past year and has a beta of 1.17, making it risky in the short term. The lack of analyst coverage (only one analyst) adds uncertainty. For investors with a 3-5 year horizon, the current valuation provides a margin of safety, but near-term downside to the 52-week low of $71.88 is possible.
HLNE is more suitable for long-term investment due to its high volatility and deep downtrend. The stock has a beta of 1.17 and has fallen 47.1% over the past year, making it risky for short-term traders. However, its strong fundamentals (net margin 32.8%, ROE 27.2%) and attractive forward PE of 11.0x suggest it could be a good long-term hold for patient investors. A minimum holding period of 3-5 years is recommended to allow for mean reversion and recovery in private markets. Short-term trading is not advised given the lack of momentum and limited catalysts.
